Attached files
file | filename |
---|---|
EX-23.1 - EX-23.1 - Tenaya Therapeutics, Inc. | d176180dex231.htm |
EX-5.1 - EX-5.1 - Tenaya Therapeutics, Inc. | d176180dex51.htm |
As filed with the Securities and Exchange Commission on July 29, 2021.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
Under
The Securities Act of 1933
TENAYA THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware | 2836 | 82-3789973 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
171 Oyster Point Boulevard, 5th Floor
South San Francisco, CA 94080
(650) 825-6990
(Address, including zip code, and telephone number, including area code, of Registrants principal executive offices)
Faraz Ali, M.B.A.
Chief Executive Officer
Tenaya Therapeutics, Inc.
171 Oyster Point Boulevard, 5th Floor
South San Francisco, CA 94080
(650) 825-6990
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Kenneth A. Clark Jennifer Knapp Jennifer Fang Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, CA 94304 (650) 493-9300 |
Alan F. Denenberg Stephen Salmon Davis Polk & Wardwell LLP 1600 El Camino Real Menlo Park, CA 94025 (650) 752-2000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ Registration No. 333-257820
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| ||||||||
| ||||||||
Title of Each Class of Securities to be Registered |
Amount Registered(1) |
Proposed Offering Price |
Proposed Maximum Aggregate |
Amount of Registration Fee(2) | ||||
Common stock, $0.0001 par value per share |
2,300,000 |
$15.00 | $34,500,000 | $3,764 | ||||
| ||||||||
|
(1) | Represents only the additional number of shares being registered and includes 300,000 additional shares of common stock that the underwriters have the option to purchase. Does not include the securities that the registrant previously registered on the registration statement on Form S-1 (File No. 333-257820). |
(2) | The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities at an aggregate offering price not to exceed $184,000,000 on a registration statement on Form S-1 (File No. 333-257820), which was declared effective by the Securities and Exchange Commission on July 29, 2021. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, an additional amount of securities having a proposed maximum aggregate offering price of $34,500,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters option to purchase additional shares. |
This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
Tenaya Therapeutics, Inc., a Delaware corporation (Company), is filing this registration statement with the Securities and Exchange Commission pursuant to Rule 462(b) under the Securities Act of 1933, as amended. This registration statement relates to the initial public offering of securities contemplated by the registration statement on Form S-1 (File No. 333-257820) originally filed on July 9, 2021, as amended (Prior Registration Statement), and which the Securities and Exchange Commission declared effective on July 29, 2021.
The Company is filing this registration statement for the sole purpose of increasing by 2,300,000 shares the number of shares of its common stock, par value $0.0001 per share, to be registered for sale, 300,000 of which may be sold by the Company upon exercise of the underwriters option to purchase additional shares solely to cover over allotments, if any. The additional shares that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement, and all exhibits to the Prior Registration Statement, are hereby incorporated by reference into this registration statement.
The required opinions and consents are listed on the Exhibit Index attached hereto and are filed herewith.
EXHIBIT INDEX
Exhibit Number |
Description | |
5.1 | Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation. | |
23.1 | Consent of Independent Registered Public Accounting Firm. | |
23.2 | Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1). | |
24.1 | Power of Attorney (see page II-6 of the Registration Statement on Form S-1 (File No. 333-257820) filed on July 9, 2021). |
II-1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, California, on July 29, 2021.
TENAYA THERAPEUTICS, INC. | ||
By: |
/s/ Faraz Ali, M.B.A. | |
Faraz Ali, M.B.A. | ||
Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Faraz Ali, M.B.A. |
Chief Executive Officer and Director |
July 29, 2021 | ||
Faraz Ali, M.B.A. |
(Principal Executive Officer) |
|||
/s/ Leone D. Patterson, M.B.A. |
Chief Financial and Business Officer |
July 29, 2021 | ||
Leone D. Patterson, M.B.A. |
(Principal Financial and Accounting Officer) |
|||
* |
Director |
July 29, 2021 | ||
Eli Casdin, M.B.A. |
||||
* |
Director |
July 29, 2021 | ||
Jin-Long Chen, Ph.D. |
||||
* |
Director |
July 29, 2021 | ||
David V. Goeddel, Ph.D. |
||||
* |
Director |
July 29, 2021 | ||
JeenJoo (JJ) Kang, Ph.D. |
||||
* |
Director |
July 29, 2021 | ||
Deepak Srivastava, M.D. |
||||
* |
Director |
July 29, 2021 | ||
Catherine Stehman-Breen, M.D. |
||||
* |
Director |
July 29, 2021 | ||
Jeffrey T. Walsh, M.B.A. |
||||
* |
Director |
July 29, 2021 | ||
R. Sanders (Sandy) Williams, M.D. |
* By: |
/s/ Faraz Ali, M.B.A. | |
Faraz Ali, M.B.A. | ||
Attorney-in-fact |
II-2